Novogen is an Australian biotechnology company listed on both the Australian Securities Exchange (NRT) and NASDAQ (NVGN).

Novogen owns two proprietary drug technology platforms that are first-in class and which the Company believes will be the foundation that will enable us to grow into a major global bio-pharmaceutical force.

The offer to institutional and sophisticated investors will open on November 3 and close on November 7. For more information about the offer please click here.

Here's an interview with CEO Dr Graham Kelly: